What Biofarm does

Biofarm Sp. z o.o. is a privately held, family-owned Polish pharmaceutical manufacturer founded in 1988 and headquartered in Poznań. The company operates a single EU GMP-certified production facility supported by an in-house Research & Development Centre, producing prescription (RX) medicines, over-the-counter (OTC) drugs, dietary supplements, and cosmetics. Its therapeutic focus spans neurology, cardiology, psychiatry, and internal medicine, with a portfolio of over 180 registered products, of which approximately 80% are developed in-house and 13 are protected by patent applications covering innovative formulations. Biofarm has established multiple first-in-Poland and first-in-Europe launches, including Atrox (atorvastatin, 2007), Bioprazol Bio (first Polish OTC omeprazole, 2009), Biomentin (first European memantine generic, 2012), Tamivil (patented Polish oseltamivir, 2018), Proaxon (first Polish cyticoline, 2018), and Solcidiol (first Polish calcifediol, 2019).

The business model is B2B-led, distributing through wholesalers and pharmacies in Poland, supported by a dedicated export department selling to 37 countries across four continents. Biofarm employs over 450 people, has invested more than 100 million PLN in R&D and modernised production equipment over 13 years, and expanded its production footprint by over 450 m² between 2018 and 2020. In 2025, the company received the Eurasian Union GMP certificate, complementing its longstanding EU GMP certification, and reached a production milestone of over 1 million 75 mg packages of Tamivil. Ownership remains 100% with the Szwarczyński family, with no public listing, no external investors, and no disclosed revenue. The company is funded by reinvested earnings, EU research grants totalling approximately 30 million PLN across 16 contests, and a PLN 6,000,000 share capital base.

Name

Biofarm

Legal name

Biofarm Sp. z o.o.

Website

https://biofarm.pl

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

251–500 employees

Short description

Biofarm is a family-owned Polish pharmaceutical manufacturer producing prescription medicines, OTC drugs, and dietary supplements in neurology, cardiology, psychiatry, and internal medicine. Operating from a single EU GMP-certified facility in Poznań, the company exports to 37 countries across four continents.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Generic Hospital & Institutional Products (HLAIABAL), Weight Management & Metabolic Supplements (CRADAGAG)

Keywords

• Generic pharmaceuticals
• Prescription medicines
• OTC drugs
• Dietary supplements
• Contract manufacturing

Headquarters

HQ city

Poznan

HQ country

Poland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical product sales (RX prescription medicines): Sales of prescription medicines (RX) covering cardiology, neurology, psychiatry and internal medicine therapeutic areas. Products include Nebicard (nebivolol), Pantopraz (pantoprazol), Metoprolol Biofarm ZK, Biomentin (memantine), Vicebrol (vinpocetine), Atrox (atorvastatin), Artigo (cinnarizine+dimenhydrinate), Aciprex (escitalopram), Asertin (sertraline), Amertil (cetirizine), Sedival, Tamivil, Noctis, Diured, Liprox, Losacor, Losacor HCT, Betanil Forte, Triacyt MR, Pulsaren, Theospirex retard, Proaxon, Aspicam (meloxicam), Lapixen, Tiocolis, Solcidiol, Folifem. Sold through wholesalers and pharmacies in Poland and export markets.
2. OTC drug sales (over-the-counter): Sales of OTC medicines including Vigalex vitamin D3 (1000, 2000, 4000 IU), Magnefar B6 Forte and Magnefar B6 Bio (magnesium + B6), Biotynox/Biotynox Forte (biotin), Ginkofar line (ginkgo biloba leaf dry extract 40/80/120/240 mg), Tribux Bio (trimebutine), Amertil Bio, Halset, Bioprazol Bio Max. Sold via pharmacy retail channel.
3. Dietary supplements sales: Sales of dietary supplements including Vigalex D3+K2, Magnefar B6 Cardio, Prewenit Balance D, Prewenit Intensiv B, Neurotynox D, Artrostav Complex D3, Cemax Forte, Cemax, Sinusal Extra. Distributed via pharmacy and retail channels.
4. Export sales (international): Export of pharmaceutical products to international markets; commenced in 2002. Rosuvastatin was launched in 17 countries in 2022; Tamivil positioned as a leader with over 1 million packages produced in 2025. Biofarm products present in 37 countries on 4 continents as of 2025. Managed by dedicated Export Department ([email protected]).

Pricing tiers

Go-to-market motion4 records

Core offering

Biofarm manufactures and supplies a portfolio of 180+ registered pharmaceutical products across prescription (RX) medicines, over-the-counter (OTC) drugs, dietary supplements, and cosmetics, with ~80% of formulations developed in-house. The portfolio spans cardiology, neurology, psychiatry and internal medicine therapeutic areas and is sold through wholesalers and pharmacies in Poland and exported to 37 countries on four continents, with key innovations including first-in-Poland launches of atorvastatin, OTC omeprazole, memantine, oseltamivir, and vitamin D3 lines.

Product overview

Biofarm Sp. z o.o. operates a single integrated pharmaceutical manufacturing business (no SaaS platform) organized around three core product categories developed and produced at its EU GMP-certified facility in Poznań, Poland: (1) RX (prescription) medicines spanning cardiology, neurology, psychiatry, and internal medicine — including flagship products such as Nebicard (nebivolol), Pantopraz (pantoprazole), Atrox (atorvastatin), Biomentin (memantine), Vicebrol (vinpocetine), Tamivil (oseltamivir), Proaxon (citicoline), Artigo (cinnarizine+dimenhydrinate), Asertin (sertraline), Aciprex (escitalopram), Metoprolol Biofarm ZK (metoprolol succinate), Amertil (cetirizine), and Aspicam (meloxicam); (2) OTC drugs including the memory-support Ginkofar line (40/80/120/240 mg Ginkgo biloba), Bioprazol Bio Max (OTC omeprazole), the Vigalex vitamin D3 line (1000/2000/4000 IU), Magnefar B6 Forte / Magnefar B6 Bio, Biotynox / Biotynox Forte (biotin), Noctis Noc (doxylamine sleep aid), and Trymigan (OTC trimebutine); and (3) dietary supplements such as Vigalex D3+K2, Magnefar B6 Cardio, Prewenit Balance D, Prewenit Intensiv B, Neurotynox D, Artrostav Complex D3, Cemax / Cemax Forte, and Sinusal Extra. Approximately 80% of the portfolio is developed in-house at Biofarm's R&D Centre, and the company holds 13 patent applications covering innovative formulations in oncology, cardiology, psychiatry, and internal medicine. Products are exported to 37 countries across four continents, with key first-in-Poland innovations including Atrox (2007), Bioprazol Bio (2009), Biomentin (2012), Lapixen (2014), Ginkofar Extra (2015), Tribux Bio (2016), Proaxon (2018), Tamivil (2018), Tiocolis (2018), Noctis (2019), Artigo (2019), Nebicard 10 mg (2019), Biotynox Forte (2019), and Solcidiol (2019).

Differentiator

Problem solved

Functional benefit

Brands

• Ginkofar: OTC/RX line based on Ginkgo biloba extract (40mg, 80mg, 120mg, 240mg doses)
• Bioprazol Bio
• Magnefar B6 / Magnefar B6 Forte / Magnefar B6 Cardio
• Vigalex / Vigalex Forte / Vigalex Max / Vigalex D3+K2
• Biotynox / Biotynox Forte
• Sedival
• Tamivil
• Diured
• Proaxon
• Artigo
• Noctis
• Atrox
• Biomentin
• Lapixen
• Tribux Bio
• Tiocolis
• Nebicard
• Solcidiol
• Pantopraz
• Metoprolol Biofarm ZK
• Asertin
• Aciprex
• Vicebrol / Vicebrol Forte
• Amertil / Amertil Bio
• Aspicam
• Artigo
• Cemax / Cemax Forte
• Prewenit Balance D / Prewenit Intensiv B
• Neurotynox D
• Artrostav Complex D3
• Sinusal Extra

Products and services

• Atrox (Atorvastatin 10/20/40/80 mg) Atorvastatin tablets (10–80 mg) for hypercholesterolaemia and prevention of cardiovascular events; the first Polish atorvastatin (launched 2007); sold as RX prescription medicine via wholesalers and pharmacies.
• Biomentin (Memantine 10/20 mg) Memantine hydrochloride tablets (10/20 mg) for moderate-to-severe Alzheimer's disease; the first memantine generic in Europe (launched 2012); sold as RX prescription medicine.
• Tamivil (Oseltamivir 75 mg) Patented small-tablet oseltamivir formulation (75 mg) for influenza treatment; the first Polish oseltamivir (launched 2018) and a Biofarm production leader with 1M+ packages produced in 2025; sold as RX prescription medicine.
• Proaxon (Citicoline) Cyticoline-based neurology medicine; the first and only cyticoline-containing medicine in Poland (launched 2018); sold as RX prescription medicine.
• Nebicard 10 mg (Nebivolol) Nebivolol 10 mg beta-blocker for essential hypertension, chronic stable heart failure, and symptomatic stable coronary artery disease; the first nebivolol 10 mg in Poland (launched 2019); sold as RX prescription medicine.
• Pantopraz 20/40 mg (Pantoprazole) Pantoprazole 20/40 mg enteric-coated tablets for reflux oesophagitis, H. pylori eradication, gastric/duodenal ulcer, and Zollinger-Ellison syndrome; sold as RX prescription medicine.
• Vicebrol / Vicebrol Forte (Vinpocetine 5/10 mg) Vinpocetine 5/10 mg tablets for chronic cerebral circulatory insufficiency, vascular dementia, and adjunctive treatment of choroidal/retinal circulatory disorders; sold as RX prescription medicine.
• Aciprex (Escitalopram 10/20 mg) Escitalopram 10/20 mg SSRI for major depressive episodes, panic disorder, social phobia, OCD, and generalized anxiety disorder; sold as RX prescription medicine.
• Asertin 50/100 mg (Sertraline) Sertraline 50/100 mg SSRI for major depression, panic disorder, OCD, social anxiety disorder, and PTSD; sold as RX prescription medicine.
• Metoprolol Biofarm ZK 23.75/47.5 mg Metoprolol succinate extended-release 23.75/47.5 mg for hypertension, angina, cardiac arrhythmias, post-MI prophylaxis, migraine prophylaxis, and stable symptomatic heart failure; sold as RX prescription medicine.
• Artigo (Cinnarizine 20 mg + Dimenhydrinate 40 mg) Cinnarizine 20 mg + dimenhydrinate 40 mg tablets for treatment of vertigo symptoms of various origins; the first generic of this combination in Poland (launched 2019); sold as RX prescription medicine.
• Aspicam 15 mg (Meloxicam) Meloxicam 15 mg NSAID for symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; sold as RX prescription medicine.
• Lapixen (Lacidipine) Lacidipine antihypertensive; the first lacidipine generic drug in Poland (launched 2014); sold as RX prescription medicine.
• Tiocolis (Thiocolchicoside) Thiocolchicoside muscle relaxant; the first and only thiocolchicoside-based medicine in Poland (launched 2018); sold as RX prescription medicine.
• Solcidiol (Calcifediol) Calcifediol vitamin D metabolite supplement product; the first calcifediol product in Poland (launched 2019); sold as RX prescription medicine.
• Sedival (RX) RX medicine in Biofarm's neurology/internal medicine portfolio; sold as RX prescription medicine via wholesalers and pharmacies.
• Diured (RX) RX diuretic in Biofarm's cardiovascular portfolio; sold as RX prescription medicine.
• Losacor / Losacor HCT (Losartan ± HCTZ) Losartan and losartan + hydrochlorothiazide combination antihypertensive medicines in Biofarm's RX portfolio; sold as RX prescription medicine.
• Betanil Forte (RX) RX cardiovascular medicine in Biofarm's RX portfolio; sold as RX prescription medicine.
• Triacyt MR (RX) Modified-release RX cardiovascular preparation in Biofarm's RX portfolio; sold as RX prescription medicine.
• Pulsaren 10/20 (RX) RX cardiovascular medicine in Biofarm's RX portfolio; sold as RX prescription medicine.
• Theospirex retard 150/300 mg Theophylline prolonged-release bronchodilator (150/300 mg); Theospirex retard 300 mg was Biofarm's first drug in production (1991); sold as RX prescription medicine.
• Amertil (Cetirizine 10 mg) Cetirizine hydrochloride 10 mg antihistamine for seasonal/perennial allergic rhinosinusitis and chronic idiopathic urticaria; sold as RX prescription medicine.
• Noctis (Doxylamine) Doxylamine-based nighttime sleep-support medicine; the first doxylamine-based product in Poland (launched 2019); sold as RX prescription medicine.
• Ginkofar (Ginkgo biloba 40/80/120 mg) Ginkgo biloba leaf dry extract tablets (40/80/120 mg) supporting memory and cognitive function; Biofarm's first in-house developed product (1996); sold as OTC drug via pharmacies.
• Ginkofar Extra (Ginkgo biloba 240 mg) High-dose Ginkgo biloba leaf dry extract 240 mg tablet; the first and only 240 mg Ginkgo Biloba dose in Poland (launched 2015); sold as OTC drug via pharmacies.
• Bioprazol Bio Max (Omeprazole OTC) OTC omeprazole for gastric reflux; Bioprazol Bio (2009) was the first omeprazole available without prescription in Poland; sold as OTC drug via pharmacies.
• Vigalex (Vitamin D3 1000/2000/4000 IU line) Vitamin D3 OTC line in 1000/2000/4000 IU dose strengths supporting immunity and bone health; launched in 2020 (Vigalex Bio, Forte, Max) establishing Biofarm as a Vitamin D3 expert; sold as OTC drug via pharmacies.
• Magnefar B6 Forte / Magnefar B6 Bio Magnesium + Vitamin B6 combinations in higher-dose (Magnefar B6 Forte) and standard (Magnefar B6 Bio) variants for fatigue, cramps and magnesium deficiency symptoms; launched as OTC in 2019; sold via pharmacy retail channel.
• Biotynox / Biotynox Forte (Biotin 5/10 mg) Biotin (vitamin B7) tablets in 5 mg and 10 mg strengths; Biotynox Forte (2019) was the first drug in Poland with the highest 10 mg biotin dose; sold as OTC drug via pharmacies.
• Trymigan (OTC Trimebutine) OTC trimebutine product for abdominal/GI symptom relief; Tribux Bio (2016) was the first OTC trimebutine in Europe; sold as OTC drug via pharmacies.
• Noctis Noc (OTC Sleep Aid) Nighttime sleep-support OTC product based on doxylamine; sold via pharmacy retail channel.
• Melatonina (OTC) Melatonin-based OTC sleep and circadian rhythm support product; sold via pharmacy retail channel.
• Amertil Bio (OTC Cetirizine) OTC cetirizine-based antihistamine for allergic rhinitis and chronic idiopathic urticaria; sold via pharmacy retail channel.
• Soyfem (Soy Isoflavones) Soy isoflavone OTC/supplement for menopausal symptom relief; multiple-time 'Product of the Year' in its category (2005-2011); sold via pharmacy and retail channels.
• Vigalex D3+K2 (Dietary Supplement) Dietary supplement combining Vitamin D3 with Vitamin K2 to support bone health; distributed via pharmacy and retail channels.
• Magnefar B6 Cardio (Dietary Supplement) Magnesium + Vitamin B6 dietary supplement positioned for cardiovascular support; distributed via pharmacy and retail channels.
• Prewenit Balance D (Dietary Supplement) Dietary supplement in Biofarm's Prewenit line supporting micronutrient balance with Vitamin D; distributed via pharmacy and retail channels.
• Prewenit Intensiv B (Dietary Supplement) Dietary supplement in Biofarm's Prewenit line with intensified B-vitamin composition; distributed via pharmacy and retail channels.
• Neurotynox D (Dietary Supplement) Dietary supplement combining neurotropic vitamins and Vitamin D for nervous-system support; distributed via pharmacy and retail channels.
• Artrostav Complex D3 (Dietary Supplement) Joint-and-bone dietary supplement with Vitamin D3; distributed via pharmacy and retail channels.
• Cemax / Cemax Forte (Vitamin C Dietary Supplements) Vitamin C dietary supplements in regular and Forte dose; distributed via pharmacy and retail channels.
• Sinusal Extra (Dietary Supplement) Dietary supplement supporting sinus and upper respiratory tract health; distributed via pharmacy and retail channels.
• Biofarm Cosmetics Line Pharmaceutical-grade cosmetics product line manufactured at the Poznań facility; sold via pharmacy and retail channels.

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Polpharma: Poland's largest pharmaceutical manufacturer and the most direct domestic peer. Operates a similar generics-plus-OTC model with Rx focus on cardiology, neurology and internal medicine, and exports to CEE/CIS markets — directly overlapping with Biofarm's product, channel and geographic footprint.
• Adamed Pharma: Polish family-owned pharma company with parallel portfolio strategy: in-house developed generics in cardiology, neurology and psychiatry, plus OTC and dietary supplements, with growing CEE export presence. Closely comparable in therapeutic mix, ownership structure and Polish-CEE GTM motion.
• KRKA: Slovenian-headquartered generic pharmaceutical manufacturer with a broad Rx portfolio in cardiology, neurology and psychiatry and a multi-continent export footprint including strong CEE/CIS coverage. Comparable in generics-first business model, vertical manufacturing, and emerging-market expansion playbook.
• Gedeon Richter: Hungarian pharmaceutical company with a generic-heavy portfolio across CNS, cardiology and women's health, plus OTC/supplement extensions, and an export footprint spanning CEE, CIS and Western Europe. Highly comparable therapeutic focus and CEE-centric GTM.
• Zentiva: European generic and OTC pharmaceutical manufacturer headquartered in Prague with broad pan-European presence. Operates the same generics-plus-OTC-plus-supplement model in cardiology, neurology and internal medicine, with comparable reliance on European reimbursement systems.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with a broad generics, specialty and OTC portfolio. Competes with Biofarm across multiple molecules (e.g., memantine, atorvastatin, nebivolol, omeprazole) but at vastly larger scale and global reach.
• Sandoz: Novartis's generics and biosimilars division; one of the world's largest manufacturers of off-patent medicines including antibiotics, cardiovascular and CNS generics. Competes with Biofarm on global tender pricing across overlapping molecules.
• Stada Arzneimittel: German generics, specialty and consumer healthcare company with strong European distribution and CEE presence. Overlaps with Biofarm in generics, OTC and dietary supplements, particularly through its Central European footprint.
• Viatris: Global healthcare company formed from the Mylan-Upjohn merger; offers a broad portfolio of generics, branded and OTC products worldwide, including cardiology and CNS molecules overlapping with Biofarm's Rx portfolio.

Emerging players

• Alvogen: US-headquartered but with significant Central and Eastern European operations (including Alvogen CEE), focused on generics, biosimilars and OTC across emerging markets. Comparable to Biofarm in CEE export-led generics strategy, though broader in biosimilars.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Biofarm-1943700492544978
• LinkedInlinkedin.com/company/biofarm-sp-z-o-o-
• Xx.com/BiofarmPoland

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biofarm